Clinical Trials Browser

INDUSTRY × tenalisib × Clear all

NCT04204057 2024-08-13

Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Phase 2 Completed

21 enrolled 12 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05021900 2024-08-13

Efficacy and Safety of Tenalisib (RP6530), in Patients With Locally Advanced or Metastatic Breast Cancer

Phase 2 Completed

40 enrolled 12 charts

Breast Neoplasms

NCT03711604 2024-05-08

Compassionate Use Study of Tenalisib (RP6530)

Phase 1/2 Completed

17 enrolled 9 charts

Other hematologic neoplasm

Hematologic Neoplasms

NCT03770000 2022-10-28

Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma

Phase 1/2 Completed

33 enrolled 13 charts

Lymphoma, T-Cell

NCT05239910 2022-10-17

Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL

Phase 2 Withdrawn

Lymphoma, T-Cell, Peripheral

NCT03711578 2021-08-12

Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)

Phase 2 Completed

20 enrolled 10 charts

Lymphoma, Non-Hodgkin

NCT02567656 2020-01-13

Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma

Phase 1 Completed

58 enrolled 15 charts

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT03471351 2019-12-27

Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL

Phase 1 Terminated

Hodgkin Disease

NCT02017613 2016-06-24

PI3K

Phase 1 Completed

DermatologicLymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous